Eli Lilly and Co.’s final site and operational plan received final approval from Pleasant Prairie’s Plan Commission, clearing the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.

The Plan Commission voted unanimously Monday night on what serves as the final approval before construction can start, said village spokesman Steven Linn. Eli Lilly’s (NYSE: LLY) contractors will be able to proceed with seeking permits for the facility additions.

Eli Lilly, the Indianapolis-based drugmaker behind pharmaceuticals such as Mounjaro, acquired the 84,000-square-foot facility at 10300 128th Ave. from Nexus in April 2024 with plans to use the site for the production of injectable medicines. In December 2024, Lilly announced plans to spend $3 billion and add 750 employees in Kenosha County.

The company in December received preliminary site plan clearance from the village, which allows for site grading, early footing and foundation and underground utility work.

Eli Lilly said it needs to expand its global injectable product manufacturing network, which the company said will help to meet growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas.

The project includes a three-story office and manufacturing addition of 54,166 square feet on the west side of the building that will include a cafeteria. On the north side of the existing building, the company plans a single-story warehouse addition of 13,940 square feet featuring four dock doors.

Read more at the BizTimes.